CClinicalTrials.gg
Status unknownNCT02375568Updated Mar 2, 2015

Large-scale Expansion and Characterization of Mesenchymal Stem Cells for Clinical Application

An observational study in Knee Injuries, sponsored by Chin-Hung Chang. Status unknown at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2015-03-02.

Sponsored by Chin-Hung Chang · Observational

The sponsor has not verified this record recently (last verified Feb 2015), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
6
Sex
All
01

Study summary

According to many recent research, mesenchymal stem cells (MSC) isolated from synovial membrane and infrapatellar fat pad have higher ex vivo proliferation capacity, multipotency and ability to undergo chondrogenesis.

Based on this concept, the investigators plan to get two removed tissues (synovial membrane and infrapatellar fat pad) from patients who have an operation of total knee replacement. The investigators are going to isolate and expand MSC from these two tissues respectively, and then compare the chondrogenesis ability for clinical application. In the other hand, the investigators plan to build techniques and procedures which comply with "Good Tissue Practices (GTP)"

02

Conditions studied

  • Knee Injuries

Browse trials for

Keywords

  • mesenchymal stem cells
03

In context

Knee Injuries

249 studies on the registry are indexed under Knee Injuries; 48 are open to participants now.

This study's planned enrollment of 6 is below the median of 90 across 79 observational studies indexed under Knee Injuries.

Browse Knee Injuries studies →

Lead sponsor

Chin-Hung Chang is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patient who have an total knee replacement surgery

Inclusion criteria

Patient who have an total knee replacement surgery

Exclusion criteria

Exclusion Criteria:

Patient who don't sign the agreement

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
6 participants (estimated)
Patient registry
No

Groups and cohorts

  • 103024-F

    For patients who have an operation of total knee replacement, two removed tissues (synovial membrane and infrapatellar fat pad) will be collected for mesenchymal stem cell isolation.

    Other: 103024-F

Interventions

  • Other103024-F

    mesenchymal stem cell isolation

06

What researchers measure

Primary outcomes

  1. Cell viability ratio of synovial membrane MSC and infrapatellar fat pad MSC from the first to the tenth cell passage

    Time frame: 6 months

  2. Doubling time of synovial membrane MSC and infrapatellar fat pad MSC from the first to the tenth cell passage

    Time frame: 6 months

  3. Percentage expression of cluster differentiation 90,105, 34, 45 surface markers of synovial membrane MSC and infrapatellar fat pad MSC from the first to the tenth cell passage

    Time frame: 6 months

Secondary outcomes

  1. Alcian blue staining of synovial membrane MSC and infrapatellar fat pad MSC

    Time frame: 6 months

  2. Tyep II collagen and aggrecan gene expression of synovial membrane MSC and infrapatellar fat pad MSC

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Far Eastern Memorial Hospital
    Pan-Ciao, Taipei 220, Taiwan
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02375568
Lead sponsor
Chin-Hung Chang
Collaborators
EMO Biomedicine Corporation
Responsible party
Chin-Hung Chang (MD. PhD., Far Eastern Memorial Hospital) — Sponsor-investigator
First posted
Mar 2, 2015
Start date
May 2014
Primary completion
Aug 2015 (estimated)
Completion
Aug 2015 (estimated)
Last update
Mar 2, 2015

Study contacts

Chih-Hung Chang, MD, Ph.D
Contact
orthocch@mail.femh.org.tw
886-2-89667000 ext. 2888

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion